Uiwang-si, South Korea

Taekyung Yoo




Average Co-Inventor Count = 10.3

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2016-2017

Loading Chart...
Loading Chart...
Loading Chart...
2 patents (USPTO):

Title: Taekyung Yoo: Innovator in Pharmaceutical Compounds

Introduction

Taekyung Yoo is a notable inventor based in Uiwang-si, South Korea. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target specific receptors related to various diseases. With a total of two patents to his name, Yoo's work is paving the way for advancements in medical treatments.

Latest Patents

Yoo's latest patents include a tricyclic compound and its use, which is designed to effectively control GPR40. This compound has potential applications in the prophylaxis or treatment of diseases associated with GPR40, such as diabetes. Another significant patent involves gonadotropin-releasing hormone receptor antagonists, which can be utilized in preventing or treating a range of sex hormone-related diseases. These include conditions like endometriosis, irregular menstruation, and even Alzheimer’s disease.

Career Highlights

Taekyung Yoo is currently employed at Sk Chemicals Co., Ltd., where he continues to innovate and develop new pharmaceutical solutions. His work is characterized by a strong focus on addressing complex health issues through targeted compounds.

Collaborations

Yoo collaborates with talented coworkers, including Jae-Sun Kim and Min-Young Han, who contribute to his research and development efforts. Their combined expertise enhances the potential impact of their innovations in the pharmaceutical industry.

Conclusion

Taekyung Yoo's contributions to pharmaceutical innovations demonstrate his commitment to improving health outcomes through targeted therapies. His patents reflect a deep understanding of complex biological mechanisms and a dedication to advancing medical science.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…